Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Phasebio Pharmaceuticals Inc (PHAS)

Phasebio Pharmaceuticals Inc (PHAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,495
  • Shares Outstanding, K 49,858
  • Annual Sales, $ 10,830 K
  • Annual Income, $ -131,070 K
  • 60-Month Beta 2.57
  • Price/Sales 0.44
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PHAS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.13
  • Most Recent Earnings $-0.34 on 08/12/22
  • Latest Earnings Date 11/09/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +151,463.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0665 +5.41%
on 11/02/22
0.2250 -68.84%
on 10/14/22
-0.1059 (-60.17%)
since 09/30/22
3-Month
0.0665 +5.41%
on 11/02/22
1.3800 -94.92%
on 08/09/22
-1.0699 (-93.85%)
since 08/02/22
52-Week
0.0665 +5.41%
on 11/02/22
4.0800 -98.28%
on 11/15/21
-3.9799 (-98.27%)
since 11/02/21

Most Recent Stories

More News
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.0701 (-26.21%)
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported...

PHAS : 0.0701 (-26.21%)
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

QURE : 4.68 (-1.27%)
PHAS : 0.0701 (-26.21%)
10 Penny Stocks with > 1,000% Upside

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 0.2630 (-14.30%)
ANGN : 10.0000 (+2.04%)
CKPT : 1.7400 (+1.16%)
EFTR : 1.9600 (+1.55%)
FRLN : 6.48 (unch)
GLYC : 2.20 (-2.65%)
MGNX : 16.83 (-0.65%)
OCUP : 1.7500 (-0.57%)
PHAS : 0.0701 (-26.21%)
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PHAS : 0.0701 (-26.21%)
PTN : 1.8300 (+0.55%)
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported...

PHAS : 0.0701 (-26.21%)
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.0701 (-26.21%)
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.0701 (-26.21%)
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced...

PHAS : 0.0701 (-26.21%)
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported...

PHAS : 0.0701 (-26.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet...

See More

Key Turning Points

3rd Resistance Point 0.1114
2nd Resistance Point 0.1017
1st Resistance Point 0.0859
Last Price 0.0701
1st Support Level 0.0604
2nd Support Level 0.0507
3rd Support Level 0.0349

See More

52-Week High 4.0800
Fibonacci 61.8% 2.5468
Fibonacci 50% 2.0733
Fibonacci 38.2% 1.5997
Last Price 0.0701
52-Week Low 0.0665

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar